In a trial that included nearly 200 participants with peripheral arterial disease, a home-based exercise intervention with a group-mediated cognitive behavioural intervention component improved walking performance and physical activity in patients with peripheral arterial disease, according to a study in the July issue of JAMA.
Paola De Rango, Vascular and Endovascular Surgery, University of Perugia, Hospital S M Misericordia, Perugia, Italy, presented the five-year outcomes of 104 patients who underwent aortic debranching and thoracic endovascular aortic repair (TEVAR) at the Society for Vascular Surgery (SVS) Vascular Annual Meeting (30 May–1 June 2013, San Francisco, USA).
A third of the deaths and complications after endovascular aneurysm repair (EVAR) occur after discharge, and improving pre-discharge surveillance and post-discharge follow-up may help to identify high-risk patients and further improve 30-day outcomes after EVAR. A study presented at the Vascular Annual Meeting (29 May–1 June 2013, San Francisco, USA) also concluded that post-discharge interventions are needed for complications with high rates of occurrence after the procedure.
New findings from a study carried out by investigators from the University of Texas Medical Branch (UTMB) at Galveston, USA, have identified a lymphocyte that is responsible for the cellular inflammation of the aortic wall that causes aortic dissections.
Bard has announced the enrolment of the first patient in the Lutonix below-the-knee clinical trial at The Cardiac and Vascular Institute in Gainesville, USA. The purpose of this global, multicentre randomised investigational device exemption (IDE) trial is to compare the safety and effectiveness of the Lutonix 014 drug-coated PTA dilatation catheter to a standard angioplasty balloon for the treatment of critical limb ischaemia, according to a press release.
Lombard Medical announced on 21 June 2013 that the Aorflex delivery system has been approved for commercial use in the USA by the FDA. The Aorflex delivery system is the company’s next generation delivery system for its Aorfix stent graft, which was approved by the FDA in February 2013 (along with the previous generation delivery device) for the endovascular repair of abdominal aortic aneurysms.
AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the completion of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) Study (“PATENT-C”). AngioScore anticipates that preliminary data from this study will be available for presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference to be held this fall in San Francisco.
Medtronic is expanding its portfolio of products for endovascular aortic repair in the United States with two new medical devices: the company recently received approval from the FDA for the Endurant II Aorto-Uni-Iliac (AUI) Stent Graft System and the FDA’s 510(k) clearance for the Sentrant Introducer Sheath; both devices will be on exhibit at the Medtronic booth during the Society for Vascular Surgery’s Vascular Annual Meeting, which runs 30 May–2 June in San Francisco, USA.
Biosensors has entered into a licensing agreement with Eurocor for its drug-eluting balloon technology and related intellectual property rights in relation to the treatment of both coronary and peripheral artery disease. As a first step in this process, Biosensors will market and sell, under its own brand, drug-eluting balloons manufactured by Eurocor.
La aspirina parece ser tan buena como los anticoagulantes más caros y potentes en la prevención de la formación de coágulos sanguíneos después de una operación quirúrgica de reemplazo de cadera, según una nueva investigación.
Cardiovascular Systems, Inc. (CSI; St. Paul, MN), announced that the first patient has been enrolled in its postmarket study, LIBERTY 360°. The study is evaluating the acute and long-term clinical and economic outcomes of CSI’s orbital atherectomy system in treating peripheral arterial disease (PAD). Additionally, LIBERTY 360° is the first study of its kind to compare orbital atherectomy to all other PAD treatment options in a difficult-to-treat patient population.
Enrolment in the investigational device exemption study of the Ventana Fenestrated System has been stopped by Endologix. According to the company, after the first 120 procedures, the safety results with the device were good but there have been a high number of renal re-interventions. Endologix plans to integrate its next-generation covered renal stent in the system and conduct additional testing and training to improve future outcomes. The company also reported 22% revenue growth for the first quarter 2013.
Un estudio sugiere que los pacientes con artritis reumática tendrían alto riesgo de padecer tromboembolia venosa (TEV). En los participantes, el riesgo estaba atenuado, pero, aún así, era alto tras considerar los factores de riesgo conocidos, como la enfermedad cardiovascular (ECV), cirugías, internaciones, tratamientos farmacológicos y niveles de reactantes de fase aguda.
Aptus Endosystems, Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its 28mm Tip Reach Heli-FX™ Guide. A line extension of the original Heli-FX System, the new product enhances treatment of wide neck abdominal aortic aneurysms (AAA). The announcement comes ahead of this week’s Society of Vascular Surgery (SVS) Vascular Annual Meeting in San Francisco where the company will be launching this device as well as the recently approved Heli-FX Thoracic System.
New data on the Endurant abdominal aortic aneurysm (AAA) stent graft system (Medtronic, Inc., Minneapolis, MN) were presented at the Society for Vascular Surgery’s Vascular Annual Meeting being held in San Francisco, California. The new data demonstrate durable clinical performance through 3 years of patient follow-up.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos